Last updated: 2026-09-16 10:30:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cingulate Inc. (CING) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.09, with a market capitalisation of $75.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.16 to $11.89. This page covers its latest market performance, valuation, price trends and company information.
$75.18M | |
$5.16 | |
$1,236.00 | |
$1.80 | |
$5.17 | |
55.51K | |
214.30K | |
-- | |
$11.89 | |
$3.16 | |
-- | |
-- |
Cingulate Inc. (CING) is trading at $5.15 in pre-market trading as of 2026-09-15 23:31:00, down 0.33% ($0.02) from the previous close of $5.17
Pre-market trading shows how investors are pricing CING before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Cingulate Inc. (CING) moved from $5.10 to $5.09, representing a decline of 0.20% ($0.01).
The stock traded between $4.80 and $5.50 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 90.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.1%
CING is currently trading at $5.09, placing it 22.1% of the way from its 52-week low of $3.16 to its 52-week high of $11.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cingulate Inc. (CING) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.